Rapid Review Quiz: New Diagnostic Tests

Elwyn C. Cabebe, MD; Herbert S. Diamond, MD; Michael Stuart Bronze, MD; Helmi L. Lutsep, MD


June 13, 2022

According to the FDA's news release, the Lumipulse G Beta-Amyloid Ratio (1-42/1-40) test is intended to help assess cognitive decline in adult patients aged 55 years or older with cognitive impairment who are being assessed for Alzheimer's disease and other issues. The test is not a stand-alone diagnostic assay, and its results must be interpreted in the context of other clinical information. Lumipulse test results are consistent with PET scan results, whether positive or negative for the presence of amyloid plaques; a positive test result can also occur in older cognitively healthy people and with other neurologic conditions.

Learn more about Alzheimer's disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.